Biotage AB (publ)

LSE:0GRP Stock Report

Market Cap: SEK 12.7b

Biotage Valuation

Is 0GRP undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0GRP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
SEK 281.88
Fair Value
44.0% undervalued intrinsic discount
3
Number of Analysts

Below Fair Value: 0GRP (SEK157.9) is trading below our estimate of fair value (SEK281.88)

Significantly Below Fair Value: 0GRP is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0GRP?

Key metric: As 0GRP is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0GRP. This is calculated by dividing 0GRP's market cap by their current earnings.
What is 0GRP's PE Ratio?
PE Ratio49.5x
EarningsSEK 257.00m
Market CapSEK 12.73b

Price to Earnings Ratio vs Peers

How does 0GRP's PE Ratio compare to its peers?

The above table shows the PE ratio for 0GRP vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average44.9x
ERGO Ergomed
46.7x14.2%UK£701.1m
HVO hVIVO
7.1x-29.6%UK£123.1m
C4XD C4X Discovery Holdings
2.9x-88.3%UK£30.3m
GNS Genus
122.9x31.5%UK£970.9m
0GRP Biotage
49.5x19.5%SEK 12.7b

Price-To-Earnings vs Peers: 0GRP is expensive based on its Price-To-Earnings Ratio (49.5x) compared to the peer average (44.3x).

Price to Earnings Ratio vs Industry

How does 0GRP's PE Ratio compare vs other companies in the European Life Sciences Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
0GRP 49.5xIndustry Avg. 38.1xNo. of Companies3PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 0GRP is expensive based on its Price-To-Earnings Ratio (49.5x) compared to the European Life Sciences industry average (39.4x).

Price to Earnings Ratio vs Fair Ratio

What is 0GRP's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0GRP PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio49.5x
Fair PE Ratio22.9x

Price-To-Earnings vs Fair Ratio: 0GRP is expensive based on its Price-To-Earnings Ratio (49.5x) compared to the estimated Fair Price-To-Earnings Ratio (22.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0GRP forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 157.90
SEK 202.67
+28.4%
3.4%SEK 212.00SEK 196.00n/a3
Jan ’26SEK 160.80
SEK 202.67
+26.0%
3.4%SEK 212.00SEK 196.00n/a3
Dec ’25SEK 152.30
SEK 202.67
+33.1%
3.4%SEK 212.00SEK 196.00n/a3
Nov ’25SEK 160.09
SEK 190.67
+19.1%
11.7%SEK 212.00SEK 160.00n/a3
Oct ’25SEK 184.75
SEK 193.33
+4.6%
12.9%SEK 220.00SEK 160.00n/a3
Sep ’25SEK 196.24
SEK 191.00
-2.7%
11.8%SEK 213.00SEK 160.00n/a3
Aug ’25SEK 198.86
SEK 191.00
-4.0%
11.8%SEK 213.00SEK 160.00n/a3
Jul ’25SEK 160.50
SEK 190.00
+18.4%
11.4%SEK 210.00SEK 160.00n/a3
Jun ’25SEK 180.30
SEK 173.33
-3.9%
10.9%SEK 200.00SEK 160.00n/a3
May ’25SEK 168.00
SEK 186.67
+11.1%
10.1%SEK 200.00SEK 160.00n/a3
Apr ’25SEK 181.88
SEK 186.67
+2.6%
10.1%SEK 200.00SEK 160.00n/a3
Mar ’25SEK 175.05
SEK 186.67
+6.6%
10.1%SEK 200.00SEK 160.00n/a3
Feb ’25SEK 145.62
SEK 165.33
+13.5%
4.6%SEK 176.00SEK 160.00n/a3
Jan ’25SEK 135.00
SEK 155.00
+14.8%
3.2%SEK 160.00SEK 150.00SEK 160.802
Dec ’24SEK 125.93
SEK 155.00
+23.1%
3.2%SEK 160.00SEK 150.00SEK 152.302
Nov ’24SEK 115.70
SEK 155.00
+34.0%
3.2%SEK 160.00SEK 150.00SEK 160.092
Apr ’24SEK 131.82
SEK 211.50
+60.4%
24.3%SEK 263.00SEK 160.00SEK 181.882
Mar ’24SEK 149.83
SEK 254.00
+69.5%
3.5%SEK 263.00SEK 245.00SEK 175.052
Feb ’24SEK 162.56
SEK 239.00
+47.0%
10.0%SEK 263.00SEK 215.00SEK 145.622
Jan ’24SEK 189.75
SEK 249.00
+31.2%
5.6%SEK 263.00SEK 235.00SEK 135.002
Analyst Price Target
Consensus Narrative from 3 Analysts
SEK 201.26
Fair Value
21.5% undervalued intrinsic discount
3
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 03:39
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Biotage AB (publ) is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Samuel EnglandBerenberg
Odysseas ManesiotisBerenberg
Marcus BellanderCarnegie Investment Bank AB